X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
The Company intends to use the net proceeds for clinical development of TT-10, an adenosine receptor type 2A (A2A) inhibitor to treat A2A expressing solid tumors.
Lead Product(s): TT-10
Therapeutic Area: Oncology Product Name: TT-10
Highest Development Status: Phase I/ Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: H.C. Wainwright & Co.
Deal Size: $6.0 million Upfront Cash: Undisclosed
Deal Type: Public Offering September 29, 2023
Details:
Under theagreement, Merck will provide KEYTRUDA for Portage's Phase 1a/1b trial evaluating adenosine 2A receptor antagonist candidate, TT-10 in patients with solid tumors including prostate cancer, renal and non-small cell lung cancer.
Lead Product(s): TT-10,Pembrolizumab
Therapeutic Area: Oncology Product Name: TT-10
Highest Development Status: Phase I/ Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Merck & Co
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration September 05, 2023
Details:
TT-10 is an orally administered Portage’s adenosine 2A receptor (A2AR) antagonist candidate evaluating in patients with solid tumors including prostate cancer, renal and non-small cell lung cancer.
Lead Product(s): TT-10
Therapeutic Area: Oncology Product Name: TT-10
Highest Development Status: Phase I/ Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 26, 2023
Details:
Under the terms of the agreement, Merck will be providing KEYTRUDA for Portage Biotech’s IMPORT-201 trial, a Phase 1/2 study of PORT-2, a liposomal formulation of IMM60, for patients with NSCLC and advanced melanoma (also known as KEYNOTE E69).
Lead Product(s): IMM60,Pembrolizumab
Therapeutic Area: Oncology Product Name: IMM60
Highest Development Status: PreclinicalProduct Type: Small molecule
Partner/Sponsor/Collaborator: Merck & Co
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration November 08, 2022
Details:
TT-10, an oral small molecule drug targeting the Adenosine A2A receptor (A2AR) in patients with advanced solid tumors both as a monotherapy and in combination with other anti-cancer agents.
Lead Product(s): TT-10
Therapeutic Area: Oncology Product Name: TT-10
Highest Development Status: Phase I/ Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Tarus Therapeutics
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 14, 2022
Details:
As a result of the transaction, Portage acquires four best-in-class assets including TT-10/PORT-6, targeting different aspects of the adenosine pathway, and is now in a unique position to evaluate the role of adenosine in cancer and other diseases.
Lead Product(s): PORT-6
Therapeutic Area: Oncology Product Name: TT-10
Highest Development Status: Phase I/ Phase IIProduct Type: Small molecule
Recipient: Tarus Therapeutics
Deal Size: $53.0 million Upfront Cash: $21.0 million
Deal Type: Acquisition July 06, 2022
Details:
Translational analysis of IMM60 confirms that PORT-2 activates iNKT cells, NK cells and dendritic cells, supporting the mechanism of action to stimulate both the adaptive and innate immune system.
Lead Product(s): IMM60,Pembrolizumab
Therapeutic Area: Oncology Product Name: IMM60
Highest Development Status: Phase I/ Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Intensity Therapeutics
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 06, 2022
Details:
Portage, Stimunity and NCI will collaborate with Center for Cancer Research to advance preclinical and clinical development of STING agonists, STI-001 and anti-Receptor for Advanced Glycation End products agents, for possible synergy to enhance the efficacy of cancer vaccines.
Lead Product(s): STI-001,Undisclosed
Therapeutic Area: Oncology Product Name: STI-001
Highest Development Status: PreclinicalProduct Type: Large molecule
Partner/Sponsor/Collaborator: National Cancer Institute
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration April 25, 2022
Details:
Clinical trials were initiated in 2021 for both of Portage’s lead invariant natural killer T cell (iNKT) agonist programs, PORT-2 (a liposomal formulation iNKT agonist) and PORT-3 (a nanoparticle coformulation of Portage’s iNKT agonist packaged with an antigen).
Lead Product(s): IMM60,Pembrolizumab
Therapeutic Area: Oncology Product Name: IMM60
Highest Development Status: Phase I/ Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 31, 2022
Details:
PORT-5 (STI-001), offers a potentially first-in-class approach to developing molecules that activate the STING pathway by packaging a STING agonist in a virus-like particle (VLP), a well-tested delivery system that can be customized and targeted to specific cells.
Lead Product(s): Virus Like Particles
Therapeutic Area: Oncology Product Name: PORT-5
Highest Development Status: PreclinicalProduct Type: Large molecule
Partner/Sponsor/Collaborator: Stimunity
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 09, 2022
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
